Eiger BioPharmaceuticals

Eiger BioPharmaceuticals, Inc. engages in the development and commercialization of foundational therapies for Hepatitis Delta Virus. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Eiger BioPharmaceuticals, Inc. operates as a biopharmaceutical company, which focuses on the development of innovative therapies for rare metabolic diseases. It is also developing avexitide as a treatment for Post-Bariatric Hypoglycemia. The company was founded by David A. Cory and Glenn S. Jeffrey on November 6, 2008 and is headquartered in Palo Alto, CA.

-  Data presented in oral presentation at ENDO 2022 on June 11 -  Avexitide significantly reduced the number of hypoglycemia events and the amount of time spent in hypoglycemia -  Study included patients who had undergone gastric bypass, vertical sleeve, total gastrectomy, or Nissen fundoplication procedures PALO ALTO, Calif. , June 13, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced Phase 2b results of avexitide in patients with post-bariatric hypoglycemia (PBH) and hyperinsulinemic hypoglycemia (HH) after other gastrointestinal surgeries, demonstrating statistically significant reductions in hypoglycemia and meeting the primary and secondary endpoints of the study.

Eiger BioPharmaceuticals Announces New Data Supporting Broader Potential of Avexitide in Patients with Post-Bariatric Hypoglycemia and Hyperinsulinemic Hypoglycemia After Gastrointestinal Surgeries

Arbutus Biopharma

ContraFect

IVERIC bio Inc

Eli Lilly

Pfizer

SQZ Biotechnologies

Three weeks ago, I suggested that the severe correction in biopharmaceutical stocks had ended. I expect the bottoming process to be choppy with a bias to the upside. The antecedent cause of the decline was the "Class of 2021 IPOs", which featured many companies with preclinical compounds, yet valuations exceeded $1 billion.

Biopharmaceutical Stocks: The Bottoming Process Is Playing Out

-  Presentations Showcase Eiger's Innovative Therapies for Hepatitis Delta Virus PALO ALTO, Calif. , June 8, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced four abstracts to be presented at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022 taking place June 22-26 in London, United Kingdom.

Eiger BioPharmaceuticals Announces Multiple Presentations at the European Association for the Study of the Liver (EASL) International Liver Congress™ 2022

Eiger nets approximately $11M after retiring its existing debt facility Immediately bolsters cash position and provides access to an additional $35M in non-dilutive capital on clinical and regulatory milestones PALO ALTO, Calif. , June 7, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it has entered into a term loan agreement with an affiliate of Innovatus Capital Partners, LLC (Innovatus) for up to $75 million and a stock purchase agreement for Innovatus to purchase $5 million of the Company's stock.

Eiger BioPharmaceuticals Enters into $75M Term Loan Agreement and $5M Stock Purchase Agreement with Innovatus Capital Partners to Refinance Existing Debt Facility and Further Strengthen Cash Position Ahead of Key Milestones

PALO ALTO, Calif. , June 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, June 8, 2022 at 9:00 AM ET in New York City.

Eiger BioPharmaceuticals to Present at the Jefferies Global Healthcare Conference

If authorized, Zokinvy® (lonafarnib) will be the first and only treatment approved in Europe to treat Hutchinson-Gilford progeria syndrome and processing-deficient progeroid laminopathies - collectively known as progeria. CHMP based its opinion on the results of data demonstrating Zokinvy increased survival by 4.3 years in children and young adults with HGPS.

Eiger Receives Positive CHMP Opinion for Zokinvy as a Treatment for Hutchinson-Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies

PALO ALTO, Calif , May 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that David Cory, President and CEO, will present a company overview at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022 at 10:30 AM ET in Miami, Florida.

Eiger BioPharmaceuticals to Present at H.C. Wainwright Global Investment Conference

PALO ALTO, Calif. and OSAKA, Japan , May 10, 2022 /PRNewswire/ -- Eiger Biopharmaceuticals Inc. ("Eiger", Nasdaq: EIGR) and AnGes Inc. ("AnGes", TYO: 4563) today announced that the companies entered into an agreement for the regulatory approval, marketing, and distribution of Zokinvy® (lonafarnib) for the treatment of Hutchinson-Gilford progeria syndrome (HGPS or progeria) and processing-deficient progeroid laminopathies (PL) in Japan.

Eiger BioPharmaceuticals and AnGes Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® (lonafarnib) in Japan

Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR ) Q1 2022 Earnings Conference Call May 5, 2022 4:30 PM ET Company Participants Sarah Mathieson - Senior Vice President-Corporate Affairs David Cory - President & Chief Executive Officer Ingrid Choong - Senior Vice President-Clinical Development Eldon Mayer - Chief Commercial Officer Sri Ryali - Chief Financial Officer Colleen Craig - Vice President-Metabolic Diseases Conference Call Participants Ashik Mubarack - Citi Bert Hazlett - BTIG Luke Herrmann - Baird Michael Higgins - Ladenburg Thalmann Operator Good day, ladies and gentlemen, and welcome to the Eiger BioPharmaceuticals First Quarter 2022 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.

Eiger BioPharmaceuticals, Inc. (EIGR) CEO David Cory on Q1 2022 Results - Earnings Call Transcript

Eiger BioPharma (EIGR) delivered earnings and revenue surprises of 3.03% and 30.03%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Eiger BioPharmaceuticals (EIGR) Reports Q1 Loss, Lags Revenue Estimates

Peginterferon lambda COVID-19 EUA Application to be Submitted in Q2 2022 Phase 3 HDV D-LIVR (lonafarnib) Study Topline Data Anticipated by Year End Zokinvy® (lonafarnib) CHMP Opinion Expected in Q2 2022 Phase 3 Avexitide Congenital Hyperinsulinism Program Initiation Planned by Year End Strong Cash Position: $153.5M Pro Forma Cash PALO ALTO, Calif. , May 5, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today reported financial results for first quarter 2022 and provided a business update.

Eiger BioPharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update

-  Phase 2 study demonstrating avexitide significantly reduced hypoglycemia in children with congenital hyperinsulinism published in Diabetes Care -  Eiger plans to initiate avexitide Phase 3 registrational program by year-end 2022 PALO ALTO, Calif. , April 25, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (NASDAQ: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced the publication of data demonstrating that treatment with avexitide significantly reduced the likelihood of fasting and protein-induced hypoglycemia in patients with congenital hyperinsulinism (HI).

Eiger Announces Publication of Positive Phase 2 Results of Avexitide in Children with Congenital Hyperinsulinism and Initiation of Phase 3 Program

-  Live Conference Call and Webcast at 4:30 PM ET  - PALO ALTO, Calif., April 21, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure hepatitis delta virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, May 5, 2022 at 4:30 PM ET to discuss its first quarter 2022 financial results and provide a business update.

Eiger BioPharmaceuticals to Host Conference Call for First Quarter 2022 Financial Results and Business Update on Thursday, May 5

Chris Kurtz Appointed Chief Technical Officer Sarah Mathieson Appointed Senior Vice President, Corporate Affairs PALO ALTO, Calif. , April 18, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced the appointments of Christopher Kurtz as Chief Technical Officer and Sarah Mathieson as Senior Vice President, Corporate Affairs.

Eiger BioPharmaceuticals Strengthens Leadership Team with New Executive Appointments

A near-term opportunity in hepatitis D virus (HDV) infection with lead asset lonafarnib supports valuation 6x higher than current share price, supported by a recent acquisition in the HDV space.

Eiger Biopharmaceuticals: Value Inflection For Lead Asset In HDV Infection On The Horizon

Eiger BioPharmaceuticals Inc (NASDAQ: EIGR) announced data from the Phase 3 TOGETHER study evaluating Peginterferon Lambda in non-hospitalized COVID-19 adult patients at high risk of progressing to severe illness. Peginterferon Lambda significantly reduced the risk of COVID-19-related.

Why Eiger BioPharmaceuticals Stock Is Jumping Today

Second largest study to date in COVID-19 outpatients (N=1,936) Highly superior compared to placebo, with a probability of superiority of 99.91% on the primary endpoint 60% reduced risk of COVID-19-related death Primary endpoint achieved across multiple SARS-CoV-2 variants, including omicron Eiger plans to submit data to FDA for Emergency Use Authorization (EUA) Management to host conference call today at 8:30 AM ET PALO ALTO, Calif. , March 17, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that Peginterferon Lambda (Lambda) significantly reduced the risk of COVID-19-related hospitalizations or emergency room visits greater than six hours by 50% (primary endpoint) and death by 60% in the Phase 3 TOGETHER study, a multi-center, randomized, double-blind, placebo-controlled study of non-hospitalized adult patients with COVID-19, who are at high risk of progressing to severe illness.

Eiger's Single-dose Peginterferon Lambda for COVID-19 Reduced Risk of Hospitalization or ER Visits by 50% in a Predominantly Vaccinated Population in Phase 3 TOGETHER Study

Live Conference Call and Webcast at 5:30 AM Pacific / 8:30 AM Eastern PALO ALTO, Calif., March 16, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 17, 2022, at 5:30 AM Pacific / 8:30 AM Eastern, to discuss the results from the Phase 3 TOGETHER study of Peginterferon Lambda for COVID-19.

Eiger BioPharmaceuticals to Host Conference Call to Discuss Phase 3 TOGETHER Study Results of Peginterferon Lambda for COVID-19 on Thursday, March 17, 2022

The average of price targets set by Wall Street analysts indicates a potential upside of 493% in Eiger BioPharma (EIGR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in Eiger BioPharma (EIGR)? Wall Street Analysts Think 493%

Eiger BioPharmaceuticals, Inc.'s (EIGR) CEO David Cory on Q4 2021 Results - Earnings Call Transcript

PALO ALTO, Calif., March 10, 2022 /PRNewswire/ -- Phase 3 COVID-19 TOGETHER (Lambda) Study Data in March 2022 Phase 3 HDV D-LIVR (Lonafarnib) Study Topline Data Planned by End of 2022 Phase 3 HDV LIMT-2 (Lambda) Study Enrolling Strong Cash Position of Approximately $106 Million as of 12/31/21 Company to Host Conference Call Today at 4:30 PM ET Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today reported financial results for fourth quarter and full year 2021 and provided a business update.

Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

PALO ALTO, Calif., Feb. 24, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today announced that it will host a conference call on Thursday, March 10, 2022 at 4:30 PM ET to discuss its fourth quarter and full year 2021 financial results and provide a business update.

Eiger BioPharmaceuticals to Host Conference Call for Fourth Quarter & Full Year 2021 Financial Results and Business Update on Thursday, March 10

PALO ALTO, Calif., Jan. 6, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious diseases, today provided the company's outlook across multiple pipeline programs and operations, including planned 2022 catalysts and milestones.

Eiger BioPharmaceuticals Announces Outlook and Planned 2022 Catalysts and Milestones

PALO ALTO, Calif., Jan. 3, 2022 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that David Cory, President and CEO, will provide a corporate update at the H.C.

Eiger BioPharmaceuticals to Present at H.C. Wainwright BioConnect 2022 Virtual Conference

PALO ALTO, Calif., Dec. 21, 2021 /PRNewswire/ -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies to treat and cure Hepatitis Delta Virus (HDV) and other serious rare diseases, today announced that the first patient has been enrolled in LIMT-2, a Phase 3 study of 48-week treatment with Peginterferon Lambda in patients with chronic hepatitis delta virus (HDV) infection.

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

News for Eiger BioPharmaceuticals Stock (EIGR)